Movement Alert｜Kelun-Biotech Biopharmaceutical Rises 4.5% in Regular Trading, Named Among June Top Golden Stocks with ASCO Data Catalyzing

Market Focus

Jun 01

On June 1, Kelun-Biotech Biopharmaceutical rose 4.5% in regular trading, trading at 465.8 HKD/share, with trading volume of approximately 84.27 million HKD. The rally was driven by the company being named one of the Top 10 Golden Stocks for June in a major investment strategy report, alongside sustained catalysis from recent ASCO annual meeting clinical data.

The company's core TROP2 ADC drug sac-TMT has initiated 17 Phase III clinical studies. Nomura previously raised its target price to 544.42 HKD and maintained a Buy rating, noting the drug demonstrated a PFS hazard ratio of 0.35 in treating PD-L1-positive non-small cell lung cancer — making it the first ADC globally to show PFS improvement in a Phase III trial for this indication. Market estimates suggest peak overseas sales could reach $15 billion, with profitability expected by next year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1133623883"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133623883\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133623883?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133623883","market":"us","top_or_hot":-1,"title":"Movement Alert｜Kelun-Biotech Biopharmaceutical Rises 4.5% in Regular Trading, Named Among June Top Golden Stocks with ASCO Data Catalyzing","media":"Market Focus","content":"<p><p>On June 1, Kelun-Biotech Biopharmaceutical rose 4.5% in regular trading, trading at 465.8 HKD/share, with trading volume of approximately 84.27 million HKD. The rally was driven by the company being named one of the Top 10 Golden Stocks for June in a major investment strategy report, alongside sustained catalysis from recent ASCO annual meeting clinical data.</p><p>The company's core TROP2 ADC drug sac-TMT has initiated 17 Phase III clinical studies. Nomura previously raised its target price to 544.42 HKD and maintained a Buy rating, noting the drug demonstrated a PFS hazard ratio of 0.35 in treating PD-L1-positive non-small cell lung cancer — making it the first ADC globally to show PFS improvement in a Phase III trial for this indication. Market estimates suggest peak overseas sales could reach $15 billion, with profitability expected by next year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Kelun-Biotech Biopharmaceutical Rises 4.5% in Regular Trading, Named Among June Top Golden Stocks with ASCO Data Catalyzing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Kelun-Biotech Biopharmaceutical Rises 4.5% in Regular Trading, Named Among June Top Golden Stocks with ASCO Data Catalyzing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-01 09:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 1, Kelun-Biotech Biopharmaceutical rose 4.5% in regular trading, trading at 465.8 HKD/share, with trading volume of approximately 84.27 million HKD. The rally was driven by the company being named one of the Top 10 Golden Stocks for June in a major investment strategy report, alongside sustained catalysis from recent ASCO annual meeting clinical data.</p><p>The company's core TROP2 ADC drug sac-TMT has initiated 17 Phase III clinical studies. Nomura previously raised its target price to 544.42 HKD and maintained a Buy rating, noting the drug demonstrated a PFS hazard ratio of 0.35 in treating PD-L1-positive non-small cell lung cancer — making it the first ADC globally to show PFS improvement in a Phase III trial for this indication. Market estimates suggest peak overseas sales could reach $15 billion, with profitability expected by next year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1133623883","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133623883","pubTimestamp":1780277970,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 1, Kelun-Biotech Biopharmaceutical rose 4.5% in regular trading, trading at 465.8 HKD/share, with trading volume of approximately 84.27 million HKD. The rally was driven by the company being...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"动感快讯|科伦生物制药常规交易涨4.5%获ASCO数据催化荣登6月顶级金股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"On June 1, Kelun-Biotech Biopharmaceutical rose 4.5% in regular trading, trading at 465.8 HKD/share, with trading volume of approximately 84.27 million HKD. The rally was driven by the company being named one of the Top 10 Golden Stocks for June in a major investment strategy report, alongside sustained catalysis from recent ASCO annual meeting clinical data.The company's core TROP2 ADC drug sac-TMT has initiated 17 Phase III clinical studies. Nomura previously raised its target price to 544.42 HKD and maintained a Buy rating, noting the drug demonstrated a PFS hazard ratio of 0.35 in treating PD-L1-positive non-small cell lung cancer — making it the first ADC globally to show PFS improvement in a Phase III trial for this indication. Market estimates suggest peak overseas sales could reach $15 billion, with profitability expected by next year.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}